膜性肾病的靶抗原发现及靶向治疗研究进展  

Research progress on target antigen discovery and targeted therapy of membranous nephropathy

作　　者：沈小芳 赵娜[1] 李克佳[1] 肖跃飞[1] Xiaofang Shen;Na Zhao;Kejia Li;Yuefei Xiao(Department of Nephrology,Aerospace Center Hospital,Beijing 100049,China)

机构地区：[1]航天中心医院肾内科,北京100049

出　　处：《中华肾病研究电子杂志》2025年第1期53-56,共4页Chinese Journal of Kidney Disease Investigation(Electronic Edition)

摘　　要：近年来对膜性肾病(MN)病理生理机制研究不断深入,逐步揭示出MN发病的关键机制是自身抗体与足细胞靶抗原的相互作用。与此同时,MN的流行病学特征显示出地域差异和不断变化的趋势,为疾病防控和诊疗提供了新的视角。本综述系统梳理了MN的最新研究进展,重点关注靶抗原发现以及以靶向治疗为代表的创新治疗策略,包括抗CD20单克隆抗体、抗补体药物、蛋白酶体抑制剂等,旨在为膜性肾病后续的研究工作以及临床诊疗提供参考。In recent years,significant advances in understanding the pathophysiological mechanisms of membranous nephropathy(MN)have revealed its underlying pathogenesis,primarily characterized by the interaction between autoantibodies and podocyte target antigens.Concurrently,the epidemiological features of MN have demonstrated regional variations and dynamic trends,offering novel insights for disease prevention and clinical management.This review systematically summarizes the latest progress in MN research,with a particular focus on the discovery of target antigens and innovative therapeutic approaches represented by targeted therapy,including anti-CD20 monoclonal antibodies,complement inhibitors,and proteasome inhibitors,in order to provide reference for the follow-up research and clinical diagnosis and treatment of membranous nephropathy.

关 键 词：膜性肾病 流行病学 靶抗原 靶向治疗 

分 类 号：R73[医药卫生—肿瘤]